EcoDrugPlus

Histone Deacetylase 5

Ensembl ID : ENSECRG00000012646
Gene Symbol: HDAC5
3 Cross references
196 Possible Orthologues:

Histone Deacetylase 6

Ensembl ID : ENSECRG00000007908
Gene Symbol: HDAC6
2 Cross references
183 Possible Orthologues:

Histone Deacetylase 7

Ensembl ID : ENSECRG00000015058
Gene Symbol: HDAC7
1 Cross references
263 Possible Orthologues:

Histone Deacetylase 8

Ensembl ID : ENSECRG00000009568
Gene Symbol: HDAC8
3 Cross references
206 Possible Orthologues:

Histone Deacetylase 9

Ensembl ID : ENSECRG00000011983
Gene Symbol: HDAC9
3 Cross references
234 Possible Orthologues:

Hydroxycarboxylic Acid Receptor 2-Like

Ensembl ID : ENSECRG00000021947
Gene Symbol: LOC114668578
2 Cross references
238 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSECRG00000013250
Gene Symbol: HCN4
3 Cross references
289 Possible Orthologues:

Hypocretin Receptor 1

Ensembl ID : ENSECRG00000012633
Gene Symbol: HCRTR1
3 Cross references
95 Possible Orthologues:

Hypocretin Receptor 2

Ensembl ID : ENSECRG00000019737
Gene Symbol: HCRTR2
3 Cross references
201 Possible Orthologues:

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 Homolog

Ensembl ID : ENSECRG00000000602
Gene Symbol: LOC114646010
3 Cross references
245 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSECRG00000000162
Gene Symbol: IKBKB
3 Cross references
198 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 1

Ensembl ID : ENSECRG00000013797
Gene Symbol: IMPDH1
3 Cross references
335 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).